Timely diagnosis of impending graft rejection is crucial for effective therapeutic intervention after allogeneic hematopoietic stem cell transplantation (SCT). We have investigated the predictive potential of early leukocyte subset-specific chimerism for graft loss in children undergoing SCT. In total, 192 pediatric patients transplanted for the treatment of malignant and non-malignant diseases after reduced-intensity or myeloablative conditioning were investigated. Surveillance of lineage-specific chimerism was initiated upon first appearance of leukocyte counts amenable to cell sorting. Graft rejection occurred in 23 patients between 24 and 492 days post-transplant (median 63 days). The first chimerism analysis of T and NK cells performed at a median of 20 days after SCT identified three different risk groups that were independent from the conditioning regimen: recipient chimerism (RC) levels in T cells below 50% indicated a very low risk of rejection (1.4%), whereas high levels of RC (490%) both in T and NK cells heralded graft loss in the majority of patients (90%) despite therapeutic interventions. RC 450% in T cells and p90% in NK cells defined an intermediate-risk group in which timely immunotherapy frequently prevented rejection. Early assessment of T-and NK-cell chimerism can therefore be instrumental in the risk assessment and therapeutic management of imminent graft rejection.
Introduction
Increasing expertise and clinical experience have rendered hematopoietic stem cell transplantation (SCT), a potentially curative therapy for a growing number of malignant and non-malignant diseases. Pediatric patients suffering from inborn neurometabolic or hematological disorders as well as heavily pretreated oncological patients benefit from the availability of tailored reduced-intensity conditioning (RIC) regimens. In the post-transplant period, survival not only depends on the cure or sustained control of the underlying disease, but also on the effective management of transplant-related complications. The implementation of immunomodulatory and anti-infectious treatment facilitates improved control of graft-versus-host disease (GvHD) and infectious complications. Moreover, close monitoring of engraftment and graft stability by chimerism testing is essential for timely initiation of intervention in case of impending graft rejection. Currently, a variety of methods are available for quantitative evaluation of chimerism levels. Reproducible and informative data can be obtained by investigating peripheral blood (PB) samples by polymerase chain reaction (PCR) techniques based on the analysis of short tandem repeats (STR) [1] [2] [3] [4] or variable number tandem repeats. 5 In sex-mismatched donor/recipient pairs, fluorescence in situ hybridization (FISH) of sex-chromosome markers provides an attractive alternative to molecular assays. 6 Although the methods of chimerism testing are well established and its importance for graft monitoring is widely accepted, there is still considerable controversy regarding the actual relevance of distinct levels of recipient chimerism (RC) and its dynamics for graft outcome. [7] [8] [9] [10] [11] [12] It is conceivable that the predictive value of chimerism levels might vary significantly depending on the underlying disease, the preparative regimen, the donor/recipient constellation and post-transplant immunosuppression.
Generally, patients undergoing RIC regimens or receiving T-cell-depleted grafts carry the highest risk of graft rejection. 13, 14 Prolonged persistence of mixed chimerism (MC) is a common finding following RIC, and close monitoring of chimerism levels is therefore recommended in this setting. By contrast, the attenuated risk of graft loss and the lower incidence of MC following myeloablative (MA) conditioning do not clearly imply the need for frequent chimerism testing. 5 As engraftment is a dynamic process with variable kinetics among individuals, appropriate timing for chimerism testing and the definition of cutoff values indicative of impending graft rejection or disease relapse have been difficult to establish. 5, 6, [15] [16] [17] [18] The plethora of different schedules and technical approaches to the detection and monitoring of chimerism renders the comparison of published data on the utility of chimerism testing for the prediction of graft rejection difficult. 6, 8, [15] [16] [17] [19] [20] [21] [22] Moreover, the significance of different leukocyte subsets for graft rejection does not necessarily correlate with their relative and absolute levels due to their distinct immunological properties. In a number of studies, analysis of chimerism in purified leukocyte fractions was shown to be more informative than testing total leukocytes. 15, 16, [22] [23] [24] [25] [26] Lineage-specific chimerism analysis appears to be advantageous owing to its higher sensitivity permitting the detection of small chimeric cell populations. Despite its diagnostic potential, it is not established as a routine parameter after RIC. The relevance of subset-specific chimerism testing after MA conditioning regimens has been discussed controversially, 5, 12, 20, 27 and studies in pediatric patients are scarce. 1, 15, 16, 18 The ultimate objective of chimerism analysis in the context of graft rejection is to identify impending graft loss as soon as possible to permit timely onset of therapeutic interventions to stabilize the graft, such as reducing immunosuppressive drugs or applying targeted donor leukocyte infusions (DLI).
To evaluate the relevance of chimerism analysis for timely prediction of graft rejection in pediatric patients, early lineage-specific chimerism analysis was performed at our center in hematopoietic SCTs following both RIC and MA conditioning regimens over a period of 10 years. The predictive value of distinct chimerism patterns for imminent rejection and the efficacy of DLI-based interventions were assessed.
Patients and methods

Patient and transplant characteristics
Between January 1998 and December 2007, 228 allogeneic transplantations were performed in the St Anna Children's Hospital in Vienna, Austria. A total of 26 transplantations were excluded from the study, including 19 transplants in patients with severe combined immunodeficiency who underwent SCT without chemo-conditioning, six second transplantations following non-engraftment and one second transplantation from the same donor on day þ 538 for relapse of the underlying disease. Lineage-specific chimerism data were not available from 10 additional patients (including cases of non-engraftment), eight of whom died before day þ 50. A total of 192 transplantations were therefore eligible for analysis. Informed consent for the study was obtained from all patients. Patient and transplant characteristics are summarized in Table 1 .
Conditioning and GvHD prophylaxis
In most patients with malignancies, MA conditioning (n ¼ 106) consisting either of total body irradiation 12 Gy plus etoposide 60 mg/kg or busulfan 16 mg/kg plus cyclophosphamide 120 mg/kg was used. Patients with non-malignant diseases received RIC regimens consisting mainly of melphalan 140 mg/m 2 , and fludarabine 160 mg/m 2 ± thiotepa 10 mg/kg. In patients receiving grafts from unrelated or mismatched donors, additional in vivo T-cell depletion was performed with anti-thymocyte globulin. Patients with non-malignant diseases undergoing RIC received anti-thymocyte globulin, MabCampath or OKT3 for in vivo T-cell depletion. GvHD prophylaxis consisted of either cyclosporin A or mycophenolate mofetil according to institutional standards, and was dose-adapted according to blood levels.
In case of MC, immunosuppression was reduced irrespective of the affected cell subset(s) in the absence of GvHD.
Intervals of analysis
Routine testing of chimerism was performed at weekly intervals from day þ 7 until day þ 40, and subsequently every other week until day þ 100. Thereafter, in the presence of stable engraftment, intervals were extended to 4 weeks. In patients who showed complete RC or MC in at least one cell population between days þ 14 and þ 40 or insufficient T-cell engraftment until day þ 40 (CD3 þ cells o1% of nucleated cells in PB), weekly monitoring was continued until complete donor chimerism (DC) was detected in all leukocyte lineages at two consecutive time points or until stable MC was observed at four consecutive time points.
Flow cytometric analysis and cell sorting
The grafts and post-transplant patient PB and bone marrow (BM) samples were analyzed by four-color quantitative flow-cytometric (FACS) analysis on the FACSCalibur (BD Biosciences, San Jose, CA, USA) using a lyse-and-wash cell preparation procedure as described in detail elsewhere. 28 The Paint-A-Gate software (BD Biosciences) was employed for data evaluation. FACS sorting of leukocyte subpopulations on the FACSVantage SE (BD Biosciences) was performed after threecolor staining in a lyse-and-wash procedure. All cell types exceeding 1% of nucleated cells were targets for cell sorting. Leukocyte subsets sorted for this study included CD33 þ 
Chimerism analysis
Specimens from patients transplanted from sex-mismatched donors (n ¼ 84) were analyzed with FISH. Cells were dropped onto slides, air-dried and fixed with increasing concentrations of ethanol. Dual-color FISH was performed according to standard procedures with commercially available probes specific for the centromeric and heterochromatic regions of the X and Y chromosomes, respectively. Depending on the number of cells available, up to 500 leukocytes were analyzed in each sorted fraction.
The samples from patients with sex-matched donors (n ¼ 108) underwent PCR analysis. DNA was extracted from nucleated cells using the QIAamp Blood kit (Qiagen, Hilden, Germany).
Recipient and donor DNA were tested before transplantation by a panel of highly polymorphic STR markers to select an informative primer set suitable for the monitoring of chimerism during the post-transplant course, as described previously. 1, 3 The detection limit was in the range of 1%.
For the analysis of patient/donor origin of cells isolated by flow sorting, the amount of DNA serving as template in individual PCR reactions was generally in the range of 1-20 ng. Upon amplification by PCR, the alleles were quantified by two different approaches: (1) gel electrophoresis and video densitometry using the Kodak Digital Science System with the 1D Image Analysis Software (Kodak, Rochester, NY, USA), and from 2003 onward, (2) capillary electrophoresis and fluorescencebased quantification using the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), as reported. 1, 22, 23 In 17 transplantations with sex-mismatched donors, both FISH and STR-PCR were applied in parallel and yielded concordant results.
Classification of cell lineages
For the purpose of our study, three groups of CD45 þ leukocyte subsets of interest were defined:
Myeloid cells: CD33 þ monocytes and CD15 þ granulocytes.
NK cells: CD3À/CD56 þ cells.
Definitions
Early subset-specific chimerism. Graft rejection. Switch to 499% RC in all cell lineages in PB and/or BM following a period of complete DC or MC in at least one leukocyte subset.
Statistical analysis
The analysis was performed using the Statistical Analysis System (SAS Institute, Cary, NC, USA). DC was categorized into three different risk groups as defined in the Results section. w 2 -test was used to investigate the association between DC and rejection rate. P-values and odds ratios were calculated for pairwise comparison between the risk groups. w 2 and Fisher's exact test were used to compare the rejection rate and the proportion of DC according to donor type.
Results
First assessment of early leukocyte-specific chimerism
In most instances (n ¼ 184), PB samples were available for chimerism testing between days þ 14 and þ 28. If PB samples could not be evaluated within this period, flow-sorted leukocytes routinely obtained from BM on day þ 28 were analyzed (n ¼ 8). The first occurrence of the cell subsets of interest including myeloid cells, T cells and NK cells at numbers permitting isolation by flow sorting and subsequent analysis of chimerism was observed at a median of 20 days (range: 14-155 days) after SCT both in patients after RIC and MA conditioning regimens. In 153 of the 192 (80%) patients, first analysis of chimerism within all cell subsets of interest could be performed within 4 weeks after transplantation. In 28 patients, T-cell engraftment occurred beyond day þ 28, and the first evaluable T-cell sorts in these cases were available at a median of 50 days post-transplant (range days þ 34 to þ 105). In 11 additional patients, chimerism data on NK cells (n ¼ 2), NK and T cells (n ¼ 1) or all cell lineages analyzed (n ¼ 8) were only available after day þ 28 (median day þ 63, range days þ 34 to þ 155) owing to technical reasons, including poor quality of clinical samples or low cell count.
Occurrence of RC at first analysis of lineage-specific early chimerism
In 100/192 (52%) instances, DC levels above 90% were observed in all cell lineages amenable to cell sorting already at the earliest time point post-transplant available for analysis, including 71/106 (67%) patients who had undergone MA conditioning, and 29/86 (34%) cases with RIC. In the remaining 92/192 (48%) patients, analysis of flow-sorted cell subsets revealed RC above 50% in at least one lineage in 15 (14%) cases following MA conditioning and in 37 (43%) cases following RIC. The distribution of different chimerism levels at the first time point of analysis is shown in Figure 1 .
Early myeloid, T-cell and NK-cell chimerism in relation to T-cell depletion and donor/recipient constellation
Chimerism within the myeloid lineage neither revealed a correlation to the in vivo or ex vivo T-cell depletion nor to the donor/recipient match (data not shown).
Of the patients who received in vivo sero-therapy to prevent graft loss (n ¼ 143), 23/72 RIC and 20/71 MA recipients had been transplanted with ex vivo T-cell-depleted grafts. Determining the influence of this procedure on chimerism levels provided different results in RIC and MA transplantations. In the RIC setting, there was no significant disparity between T-celldepleted and T-cell-replete grafts with regard to the overall occurrence of RC above 50% in the NK-and T-cell subsets. Within the T-cell population, the frequency of intermediate-as compared to high-level RC was shifted towards high-level RC in case of ex vivo T-cell depletion. In MA-SCT, high-level RC occurred mainly after ex vivo T-cell depletion both in NK and T cells. The low overall occurrence of RC above 50% in this setting precluded statistical analysis ( Table 2) .
The incidence of early T-and NK-cell RC according to the donor/recipient constellation is depicted in Table 3 . A detailed analysis of chimerism in relation to specific protocols of preparative chemotherapy and radiation was not feasible owing to the heterogeneity of the applied strategies.
Characteristics of graft rejection
Within the evaluable cohort of 192 transplant recipients, 23 rejections (12%) occurred between days þ 24 and þ 492 (median day þ 63) after transplantation. The disease-and transplantation-related characteristics of the affected patients are specified in Table 4 .
In total, 19 rejections occurred following RIC corresponding to a rejection rate of 22%, and four rejections were observed among patients who had undergone MA conditioning, indicating a rejection rate of 4% in this setting. T-cell depletion had been performed in 20/23 patients with graft rejection, either by combined in vivo and ex vivo manipulation (n ¼ 10), by in vivo T-cell depletion only (n ¼ 9) or by exclusive ex vivo CD34 þ positive selection (n ¼ 1). Following RIC, the rejection rate was 30% (3/10) in recipients of unmanipulated grafts without serotherapy, 16% (8/49) after pre-transplant in vivo T-cell depletion and 30% (8/27) after ex vivo T-cell depletion. In MA transplantations, the rejection rates in these settings were 0% (0/33), 2% (1/51) and 14% (3/22), respectively. After MA conditioning, 9% of patients had HL, 4% IL and 87% LL RC in the T-cell compartment. NK cells showed HL RC in 2%, IL RC in 1% and LL RC in 97% of patients. All patients displayed LL RC in the myeloid cell subset. IL or HL RC in a single cell compartment occurred in 13 patients. In the MA setting, two patients had IL or HL RC in two cell subsets and no patient showed IL or HL RC in all three cell subsets. NK, natural killer; RC, recipient chimerism. 
Correlation of graft rejection with results of the first analysis of early lineage-specific chimerism
In patients who experienced a graft rejection, RC levels within the T-cell population at first analysis were above 50% in 21/23 (91%), and higher than 90% in 17/23 (74%) cases (Figure 2 ). Within the NK-cell fraction, the first evaluable RC levels were above 50% in 10/23 (44%), and above 90% in 9/23 (39%) patients with ensuing graft rejection. Table 5a . The data underlying the calculation of positive and negative predictive values of early cell subset-specific chimerism for the occurrence of graft rejection are summarized in Table 5b .
Of the patients exhibiting early RC levels 490% in the T-cell population, 17/32 (53%) individuals rejected the graft (Figure 3) . Within the NK-cell lineage, high-level RC was observed in 10 cases, 9 of which (90%) experienced graft rejection. Thus, highlevel RC (490%) within T and NK cells at first analysis of chimerism revealed a positive predictive value for subsequent graft rejection of 53.1% (95% confidence interval (CI) 36-69%) (specificity 91.1%) and 90% (95% CI 60-98%) (specificity 99.4%), respectively. All patients with high-level RC in NK cells had also high-level RC in T cells, but the risk of rejection was primarily indicated by early NK-cell chimerism.
Conversely, graft rejection was a rare event in patients revealing o50% RC in T or NK cells at first analysis: among patients who met this criterion in the T-cell lineage only 2/141 (1.4%) experienced graft loss, and this level of chimerism in the NK-cell lineage was associated with graft rejection in 13/179 (7.3%) instances. Hence, first assessment of lineage-specific chimerism revealing the presence of RC levels o50% in the T-and NK-cell compartments had a negative predictive value for impending graft rejection of 98.6% (95% CI 95-99%) (sensitivity 91.3%) and 92.7% (95% CI 88-96%) (sensitivity 43.5%), respectively.
In patients with T-cell RC 450% and NK-cell RC p90% at first analysis, graft loss was observed in 12/41 (29%) cases. In this subgroup, more precise risk assessment of graft rejection was possible upon evaluation of lineage-specific chimerism over the subsequent 2 weeks.
The observation of further chimerism kinetics could be performed in 38/41 patients (93%). Persisting low levels or further decreasing levels of donor T cells within 2 weeks after the first evaluation of lineage-specific chimerism correlated with an elevated rejection rate (9/24 patients, 38%). By contrast, a rise in T-cell DC during the same period of time was associated with a relatively low occurrence of graft rejection (1/14 patients, 7%) (data not shown).
In contrast to NK and T cells, early chimerism levels in the myeloid compartment did not reveal any significant correlation with later graft rejection (data not shown).
Definition of risk groups for graft rejection according to the pattern of early T-and NK-cell chimerism. On the basis of the predictive values of different levels of early chimerism, three risk groups for impending graft Table 3 Chimerism status at first lineage-specific analysis according to donor/recipient constellation: (a) RIC and (b) MA conditioning Early T-and NK-cell chimerism predicts graft rejection after stem cell transplantation S Breuer et al rejection were defined (Figure 4 ). An overview of the chimerism parameters characterizing each risk group is provided in Table 6 .
Kinetics of chimerism in patients with graft rejection
In patients who rejected their graft, chimerism levels usually followed a characteristic pattern. Early T-and NK-cell chimerism predicts graft rejection after stem cell transplantation S Breuer et al
Two types of typical kinetics of chimerism were observed:
(1) In individuals with high-level RC in T cells only (n ¼ 22), rejection was heralded by a drop in NK-cell DC, followed by gradual loss of donor granulocytes and monocytes. In some of these patients, however, timely DLI therapy resulted in stabilization of the graft, which was indicated by a persistent increase in donor T-cell levels (n ¼ 13). (2) In patients who displayed high levels of RC both in T and NK cells (n ¼ 10), rejection was preceded by a simultaneous decrease of DC in the granulocyte and monocyte compartments. In these instances, rejection could not be prevented even by repetitive DLI, with the exception of a single patient in whom stabilization of the graft could be achieved by this treatment strategy. The patient had received haploidentical BM transplantation for acute myeloid leukemia, and relapsed with acute lymphoblastic leukemia 18 months thereafter. Following unrelated PB SCT, first lineage-specific chimerism analysis revealed high-level RC in T and NK cells. The patient received DLI at monthly intervals, starting 5 weeks after SCT for 7 months. During this period, continuously rising levels of DC were observed, and ultimately sustained DC was achieved in all lineages within 1 year post-transplant.
In contrast to the commonly observed patterns of chimerism, two patients had very unusual kinetics before graft loss. One of the patients (patient 9; Table 4 ) received RIC and underwent SCT from a matched sibling donor for treatment of stage IV renal cell carcinoma. He had low-level RC (31% in NK cells and 34% in T cells) at first analysis, and achieved MC at levels of 60-80% DC in all cell lineages. At 8 weeks after transplantation, autologous regeneration was observed, initially within the granulocyte and monocyte fractions, followed by gradual loss of donor NK and T cells over the subsequent weeks. At the same time, the patient was diagnosed with relapse of his primary tumor. At 20 weeks after SCT, graft rejection occurred despite several courses of DLI, and the patient ultimately succumbed to tumor progression.
The second patient (patient 20; Table 4 ) was the only individual displaying a low-risk chimerism profile (o10% RC 
Table 5a
Rejection rates according to the first analysis of lineage-specific RC levels Abbreviations: MA, myeloablative conditioning; NK, natural killer; RC, recipient chimerism; RIC, reduced-intensity conditioning.
Table 5b
Correlation of early T-and NK-cell chimerism with graft rejection
RC level T cells 490%
T cells 450% and o90% T cells p50% Early T-and NK-cell chimerism predicts graft rejection after stem cell transplantation S Breuer et al in all lineages) at first analysis who nevertheless experienced a very late graft rejection. She underwent BM transplantation from a matched unrelated donor for hemophagocytic lymphohistiocytosis, and lost the graft more than 14 months after transplantation. Following a period of complete DC in all lineages until about day þ 100, donor cells gradually decreased to o10% in most lineages. This was first apparent in the monocyte fraction, followed by the granulocyte and NK-cell fractions, whereas stable full DC was still maintained in the T-cell population. At that time, the patient experienced an episode of febrile nephritis, followed by prolonged autoimmune hemolytic anemia requiring intensification of immunosuppression and anti-CD20 antibody treatment. On day þ 300, donor T-cell chimerism levels had also dropped to 50%, and the graft was finally rejected 492 days post-transplant despite the administration of a stem cell boost and DLI. After rejecting a second graft from the same donor, the patient was transplanted from a new matched unrelated donor and is currently, 2.5 years after the third SCT, well and without signs of rejection.
Immunotherapeutic intervention in patients with impending graft rejection
In children displaying a particularly high risk of allograft rejection according to the currently applied criteria, treatment with a mean of two (range 1-8) DLI doses (1 Â 10 3 -1 Â 10 9 /kg) was given in addition to the reduction of immunosuppression in the attempt to prevent graft loss. This therapeutic intervention was performed in 24/32 (75%) cases with RC levels 490% in the T-cell lineage. Depending on the level of NK-cell chimerism, different response rates were observed: 6/7 cases (86%) with RC levels 490% in the NK-cell fraction rejected the graft despite treatment by DLI, whereas only 5/17 (29%) children with lower RC in NK cells lost their grafts (Table 7 ). In the remaining 12 patients, a switch from virtually complete RC in the T-cell fraction to high-level DC was observed upon DLI treatment, and none of the patients rejected the graft. Eight of 32 (25%) patients with high-level T-cell RC were not treated by DLI because of their high risk of GvHD or because donor lymphocytes were not available. Within this group, graft rejection occurred in 3/3 and 3/5 cases after MA conditioning and RIC, respectively. The responses to DLI therapy did not reveal any apparent correlation with the dose or the number of treatment cycles (data not shown). Owing to the small numbers, differences between the DLI responses observed did not reach statistical significance (not shown).
Discussion
The importance of monitoring hematopoietic chimerism after allogeneic SCT for the assessment of engraftment, graft rejection and, in patients with hematopoietic malignancies, of disease recurrence is widely accepted. 5, 6, [15] [16] [17] 29, 30 A number of earlier studies were based on the analysis of chimerism within total peripheral white blood cells. 17, 29, 31 Specific isolation of highly purified individual cell types by flow sorting facilitates the enrichment of subsets of interest representing as little as 1% of the total white blood cell count, thereby enabling the detection of chimerism patterns that would escape detection of analyses within total leukocyte populations. 1, 15, 16, 22 Lymphoid cells are known to play a major immunological role in graft rejection, and analysis of chimerism within lymphocyte cell subsets of interest can therefore be expected to provide more specific information on the crucial patho-physiological processes leading to rejection. Several reports have documented the relevance of T-and NK-cell chimerism in the prediction of graft rejection in different transplant settings, particularly in the context of RIC. 5, 6, 8, 9, 23, 24, 26, [32] [33] [34] [35] [36] [37] [38] [39] [40] To date, only few trials have addressed the correlation of chimerism patterns and graft rejection in the MA setting. 5, 20, 27, 41, 42 This study was performed to address the potential significance of lineage-specific chimerism for prediction of graft rejection at the earliest possible time point after transplantation, in order to provide a basis for timely therapeutic intervention. We have assessed the possibility of identifying a single informative time point of investigation with the aim to avoid the need for Early T-and NK-cell chimerism predicts graft rejection after stem cell transplantation S Breuer et al sequential analyses precluding very early risk assessment. Samples obtained before day þ 14 post-transplant were not considered for analysis because up to this time point remaining recipient cells are frequently detected even after MA conditioning. 17 It was technically feasible to analyze chimerism within the cell subsets of interest in PB and BM samples obtained before day þ 28 in the majority of cases irrespective of conditioning regimen, stem cell source and underlying disease. Our data indicate that the earliest possible assessment of the chimerism status within the T-and NK-cell compartments provides clinically useful information on the risk of allograft rejection. In particular, the detection of RC levels in T cells below 50% at this early time point was indicative of a very low risk of graft loss during follow-up. Only two of 141 patients (1.4%) exhibiting this level of T-cell chimerism experienced a graft rejection at very late time points, 5 and 16 months post-SCT, translating into a sensitivity of 91.3%, and a negative predictive value for subsequent graft rejection of 98.6%.
Conversely, the presence of RC levels 490% in the NK-cell subset correlated with a high probability of graft rejection (specificity 99.4%, positive predictive value 90%). The incidence of graft rejection in patients with this level of RC in the Tcell fraction alone was considerably lower (53%). These observations support the importance of assessing both NKand T-cell chimerism to determine the risk of rejection.
In patients with intermediate levels of RC (450-90%) in T cells and low or intermediate RC in NK cells at first lineagespecific chimerism analysis, the risk of rejection is also elevated, but less pronounced (Figure 4 ). In these instances, serial analyses would likely permit more accurate prediction of the allograft fate ( Figure 5 ).
It is important to bear in mind that different conditioning regimens, modes of T-cell depletion and donor/recipient constellations may be associated with different patterns of chimerism and distinct probabilities of graft rejection. In this context, the definition of chimerism patterns universally predictive for impending rejection could be of significance for treatment decisions not only in patients receiving RIC and/or T-cell depleted grafts, but also in individual patients with low inherent risk of rejection. In this study, criteria for patients with negligible versus particularly high risk of graft rejection have been defined on the basis of early subset-specific chimerism levels. The characteristics distinguishing the risk groups are applicable to patients irrespective of the transplant setting and conditioning regimen.
Remarkably, determination of lineage-specific chimerism patterns reliably identified patients at risk for rejection also after MA conditioning regimens, which is in contrast to recently published observations. 20, 27 However, in these studies the observed frequency and the cutoff levels used to define poor T-cell chimerism differed substantially from our definitions, thereby rendering direct comparison difficult.
The assignment of patients to the indicated risk categories may also have practical implications for the further diagnostic surveillance and timely therapeutic decisions. We therefore propose different schedules for the monitoring of chimerism and treatment strategies based on the risk groups defined by the first lineage-specific analysis as outlined in Figure 5 .
In patients with findings indicative of a very low risk of rejection, which applied to the majority of children included in this study (n ¼ 141, 74%), extending the intervals of chimerism testing can be considered to reduce the costs of diagnostics. The identification of patients at high risk, which comprised a small proportion of children in our study (n ¼ 10, 5%), could provide the rationale for rapid implementation of appropriate treatment modifications, and very close monitoring of the response in order to prevent graft loss. In addition, early identification of unfavorable chimerism patterns can provide a window for timely search for an alternative donor for possible re-transplantation. Moreover, it permits timely consideration and planning of alternative therapeutic options required in case of actual rejection. In the intermediate-risk group of patients (n ¼ 41, 21%), the kinetics of chimerism determined by lineage-specific analysis after 2 weeks could permit more reliable risk assessment of subsequent graft loss. It would therefore appear reasonable for this risk group to perform further diagnostic surveillance by monitoring the kinetics of chimerism at short intervals, and to utilize the results as a basis for therapeutic interventions, if pertinent. It is important to emphasize, however, that the individual clinical and disease-related parameters must be considered in addition to the levels and dynamics of donor-and recipient-derived NK and T cells for adequate clinical management of patients with MC. This includes, for example, careful assessment of the individual risk of GvHD before the administration of DLI therapy. When assessing the individual and combined impact of T-and NK-cell chimerism on graft rejection, it is of interest to review the success of clinical interventions performed in patients with different patterns of chimerism in these lineages. In line with previously reported strategies, 6, 21, 25, 29, [43] [44] [45] immunosuppressive therapy was gradually tapered in all 32 patients displaying 490% RC in the T-cell lineage, and 24/32 patients were also treated with DLI. This approach was apparently successful in the majority of cases, but failed in virtually all patients with concomitant RC levels in the NK-cell fraction 490%. High-level RC in the NK cells was not only indicative of impending graft rejection, but also appeared to herald poor response to DLI treatment. In fact, graft loss was successfully prevented by repeated DLI treatment in only one patient with high RC levels in the NK-cell fraction at first lineage-specific analysis of chimerism. It is important therefore to carefully evaluate the potential benefit of a therapeutic intervention with DLI in each patient, with regard to the risk of triggering GvHD.
The importance of donor NK cells for engraftment was described earlier, 46 and several studies in SCT patients with RIC regimens considered the informativeness of NK-cell chimerism for assessment of the risk of graft rejection as complementary 36 or even superior to T-cell chimerism. 23, 24, 26, 47 In extension of our earlier observations in RIC patients, 23 the present data indicate that the role of NK-cell chimerism also applies to individuals after MA conditioning. Our current findings suggest that the presence of high-level RC both in the T-and NK-cell subsets at first analysis after SCT may require immunomodulatory approaches beyond the reduction of immunosuppression and DLI therapy to prevent graft rejection. In view of the small numbers, however, this notion has to be interpreted with great caution and certainly requires further assessment. This study provides evidence that evaluation of lineage-specific chimerism between days þ 14 and þ 28 post-transplant is technically feasible, and offers the possibility to identify patients at very low and high risk of graft rejection, irrespective of the conditioning regimen applied. Early analysis of chimerism in the T-and NK-cell fractions may therefore have important implications for both diagnostic and therapeutic procedures aiming at successful prevention of graft loss.
